Abstract
Cancer clinical trials have been one of the key foundations for significant advances in oncology. However, there is a clear recognition within the academic, care delivery and pharmaceutical/biotech communities that our current model of clinical trial discovery and development is no longer fit for purpose. Delivering transformative cancer care should increasingly be our mantra, rather than maintaining the status quo of, at best, the often miniscule incremental benefits that are observed with many current clinical trials. As we enter the era of precision medicine for personalised cancer care (precision and personalised medicine), it is important that we capture and utilise our greater understanding of the biology of disease to drive innovative approaches in clinical trial design and implementation that can lead to a step change in cancer care delivery. A number of advances have been practice changing (e.g. imatinib mesylate in chronic myeloid leukaemia, Herceptin in erb-B2-positive breast cancer), and increasingly we are seeing the promise of a number of newer approaches, particularly in diseases like lung cancer and melanoma. Targeting immune checkpoints has recently yielded some highly promising results. New algorithms that maximise the effectiveness of clinical trials, through for example a multi-stage, multi-arm type design are increasingly gaining traction. However, our enthusiasm for the undoubted advances that have been achieved are being tempered by a realisation that these new approaches may have significant cost implications. This article will address these competing issues, mainly from a European perspective, highlight the problems and challenges to healthcare systems and suggest potential solutions that will ensure that the cost/value rubicon is addressed in a way that allows stakeholders to work together to deliver optimal cost-effective cancer care, the benefits of which can be transferred directly to our patients.
References
1.
President Obama's State of the Union Address: Remarks as Prepared for Delivery. http://go.wh.gov/SOTUMedium. 2015.
2.
European Commission: Horizon 2020, the EU framework programme for research and innovation. Brussels, European Commission, 2015.
3.
Burki T: UK and US governments to fund personalised medicine. Lancet Oncol 2015;16:e108.
4.
Siva N: UK gears up to decode 100,000 genomes from NHS patients. Lancet 2015;385:103-104.
5.
Prince MJ, Wu F, Guo Y, Robledo LMG, O'Donnell M, Sullivan R, Yusuf S: The burden of disease in older people and implications for health policy and practice. Lancet 2015;385:549-562.
6.
Morgan G, Ward R, Barton M: The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol 2004;16:549-560.
7.
Sullivan R, Purushotham AD: The Goldilocks' problem of cancer medicines. Lancet Oncol 2010;11:1017-1018.
8.
Horgan D, Paradiso A, McVie G, Banks I, Van der Wal T, Brand A, Lawler M: Is precision medicine the route to a healthy world? Lancet 2015;386:336-337.
9.
Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM: Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 2011;103:1222-1226.
10.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
11.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
12.
Piccart M, Kaufmann M: Herceptin: HER2 Status-Changing Clinical Practice - Introduction. Oxford, Pergamon-Elsevier Science, 2001.
13.
Goldman JM, Druker BJ: Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-2042.
14.
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM: Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. ASCO Annu Meet Proc 2014;32: LBA9008.
15.
Shaw A, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ: BM-32. Ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases (BM) in the ASCEND-1 trial. Neuro-oncology 2014;16: v39-v39.
16.
Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, De Pas T, Besse B, Solomon BJ, Blackhall F: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
17.
Eggermont A, Robert C, Soria JC, Zitvogel L: Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology 2014;3:e27560.
18.
Lawler M, Selby P: Personalized cancer medicine: are we there yet? Oncologist 2013;18:649-650.
19.
McNeil C: NCI-match launch highlights new trial design in precision-medicine era. J Natl Cancer Inst 2015;107:djv193.
20.
Zardavas D, Piccart-Gebhart M: Clinical trials of precision medicine through molecular profiling: focus on breast cancer. Am Soc Clin Oncol Educ Book 2015;35:e183-e190.
21.
Herper M: The cost of creating a new drug now $5 billion. Pushing big pharma to change. http://www forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine. 2013.
22.
Parmar MK, Barthel FM-S, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart A-M: Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008;100:1204-1214.
23.
Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C: American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:1277-1280.
24.
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ: A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015;26:1547-1573.
25.
Sharma MR, Schilsky RL: Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 2012;9:208-214.
26.
Parmar MK, Carpenter J, Sydes MR: More multiarm randomised trials of superiority are needed. Lancet 2014;384:283-284.
27.
Lawler M, Kaplan R, Wilson RH, Maughan T; S-CORT Consortium: Changing the paradigm - multistage multiarm randomized trials and stratified cancer medicine. Oncologist 2015;20:849-851.
28.
Siu LL, Conley BA, Boerner S, Lorusso PM: Next-generation sequencing to guide clinical trials. Clin Cancer Res 2015;21:4536-4544.
29.
Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, Parmar M: Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013;31:4562-4568.
30.
Lawler M, Maughan TS: Precision medicine for colorectal cancer patients: time to get personal. J Eur Soc Primary Care Gastro 2015, in press.
31.
Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D, Folprecht G, Roth A, Stupp R: European perspective for effective cancer drug development. Nat Rev Clin Oncol 2014;11:492-498.
32.
Conley BA, Doroshow JH: Molecular analysis for therapy choice: NCI match. Semin Oncol 2014;41:297-299.
33.
Schilsky RL: Implementing personalized cancer care. Nat Rev Clin Oncol 2014;11:432-438.
34.
The Economist: The future of cancer treatment. Up close, and personal. Economist, October 14, 2004.
35.
Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R: Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol 2015;pii:JCO. 2015.61.5997.
36.
Balogh E, Patlak M, Nass SJ: Delivering Affordable Cancer Care in the 21st Century: Workshop Summary. Washington, National Academy Press, 2013.
37.
Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-4442.
38.
Huguier M JH, Roberts PJ, Sarlomo-Rikala M, Anderson LC, Tervahartiala P, Tuveson D, et al: Effect of the tyrosine inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
39.
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
40.
Fenaux P, Le Deley M, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel M, Bowen D: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-3249.
41.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
42.
Marzo I, Naval J: Antimitotic drugs in cancer chemotherapy: promises and pitfalls. Biochem Pharmacol 2013;86:703-710.
43.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403.
44.
Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E: European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 2015;26:779-786.
45.
World Health Organization: The European Health Report 2012: Charting the Way to Well-Being. Geneva, World Health Organization, 2013.
46.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893-2917.
47.
United States Census Bureau: Population Division. Interim Projections Consistent with Census 2000 (released March 2004). Washington, US Census Bureau, 2008.
48.
Economic and Financial Affairs Directorate General: The 2009 Ageing Report: Economic and Budgetary Projections for the EU-27 Member States (2008-2060). Joint Report Prepared by the European Commission (DG ECFIN) and the Economic Policy Committee (AWG). Luxembourg, Office for Official Publications of the European Communities, 2009.
49.
Office for National Statistics: Ageing of the UK Population. London, Office for National Statistics, 2015.
50.
Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, Bray F: Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012;380:1840-1850.
51.
American Cancer Society: The Global Economic Cost of Cancer. Atlanta, American Cancer Society, 2010.
52.
Yabroff KR, Lund J, Kepka D, Mariotto A: Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomark Prev 2011;20:2006-2014.
53.
Bradley CJ, Yabroff KR, Dahman B, Feuer EJ, Mariotto A, Brown ML: Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst 2008;100:1763-1770.
54.
Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ: Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008;100:1755-1762.
55.
Zambrowski J-J: Cost of cancer in France: pharmaceutical expenditure as part of global patients' care (in French). Bull Cancer 2008;95:535-541.
56.
Araújo A, Barata F, Barroso S, Cortes P, Damasceno M, Parreira A, Santo JE, Teixeira E, Pereira R: Cost of cancer care in Portugal. Acta Med Port 2009;22:525-536.
57.
Featherstone H, Whitham L: The Cost of Cancer. London, Policy Exchange, 2010.
58.
Luengo-Fernandez R, Leal J, Gray A, Sullivan R: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14:1165-1174.
59.
Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M: Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-1619.
60.
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF: Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-980.
61.
Fojo T, Mailankody S, Lo A: Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley lecture. JAMA Otolaryngol Head Neck Surg 2014;140:1225-1236.
62.
Nowak F, Soria J-C, Calvo F: Tumour molecular profiling for deciding therapy - The French Initiative. Nat Rev Clin Oncol 2012;9:479-486.
63.
Khayat D: Innovative cancer therapies. Cancer 2012;118:2367-2371.
64.
Ginsburg GS, Kuderer NM: Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol 2012;30:4233-4242.
65.
Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL, Wolmark N: Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! For women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133-142.
66.
Kim C, Paik S: Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 2010;7:340-347.
67.
Lamond NW, Skedgel C, Rayson D, Lethbridge L, Younis T: Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 2012;133:1115-1123.
68.
Yang M, Rajan S, Issa AM: Cost effectiveness of gene expression profiling for early stage breast cancer. Cancer 2012;118:5163-5170.
69.
National Institute for Clinical Excellence: Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. London, National Institute for Health and Care Excellence, 2013.
70.
Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
71.
Hirsch FR, Bunn PA: EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433.
72.
Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009;6:519-527.
73.
Dolgin E: FDA narrows drug label usage. Nat News 2009;460:1069-1069.
74.
Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E: Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010;5:1706-1713.
75.
Djalalov S, Beca J, Hoch JS, Krahn M, Tsao M-S, Cutz J-C, Leighl NB: Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014;32:1012-1019.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
